* Most layoffs involve U.S. research sites
* Cuts do not target specific therapeutic areas
Oct 19 Amgen Inc , the world's largest
biotechnology company, is laying off 380 research and
development employees, mostly in the U.S., or about 2 percent
of the company's total workforce.
The cuts do not target particular therapeutic areas and no
sites are being shut down, a company spokeswoman said.
"These are very targeted and strategic reductions so we can
continue to allocate our R&D resources in a focused manner,"
Amgen spokeswoman Mary Klem said.
She said the layoffs involve staff at research facilities
in Thousand Oaks, California; Seattle; South San Francisco,
California; and Massachusetts. The company is in discussions
with some UK personnel regarding layoffs.
Amgen, which had 17,600 employees at the end of July,
signaled to employees last week that it planned to reorganize
"We have lots of molecules moving into later stages of
development, which means more expensive stages of development,"
She declined to comment on how much money the company aims
to save with the job cuts.
Last year, Amgen posted revenue of $15.1 billion and spent
$2.9 billion, or about 19 percent of its revenue, on R&D -- a
level that some investors have deemed too high.
Separately on Wednesday, Amgen said it had hired Anthony
Cooper, formerly with Bristol-Myers Squibb , to head its
global commercial operations.
Sales of Amgen's flagship anemia drugs have flattened over
the past few years on concerns that doctors may have been
overusing the medicines in certain patients. The company's new
bone drug denosumab is seen by many as its next blockbuster.